RTOG publications since 1996

RTOG publications since 1996

Int. J. Radiation Oncology Biol. Phys., Vol. 51, No. 3, Supplement 2, pp. 125–145, 2001 Copyright © 2001 Radiation Therapy Oncology Group Printed in t...

115KB Sizes 14 Downloads 50 Views

Int. J. Radiation Oncology Biol. Phys., Vol. 51, No. 3, Supplement 2, pp. 125–145, 2001 Copyright © 2001 Radiation Therapy Oncology Group Printed in the USA. All rights reserved 0360-3016/01/$–see front matter

PII S0360-3016(01)01795-3

RTOG PUBLICATIONS SINCE 1996

Table 1. Manuscripts published Manuscript reference

Study

Site

Scarantino C, Caplan R, Rotman M, et al. A phase I/II study to evaluate the effect of fractionated hemibody irradiation in the treatment of osseous metastases—RTOG 88–22. Int J. Radiat Oncol Biol Phys 1996; 36:37–48. Fisher J, Scott C, Stevens R, et al. Randomized phase III study comparing best supportive care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97–13. Int J Radiat Oncol Biol Phys 2000; 48:1307–1310. Schultz C, Scott C, Sherman W, et al. Pre-irradiation chemotherapy with cyclophosphamide, adriamycin, vincristine, and dexamethasone for primary central nervous system lymphomas: Initial report of Radiation Therapy Oncology Group (RTOG) protocol 88–06. J Clin Oncol 1996; 14:556–564. Simpson, JR, Scott CB, Rotman M, et al. Race and prognosis of brain tumor patients entering multicenter clinical trials—A report from the Radiation Therapy Oncology Group. Am J Clin Oncol (CCT) 1996; 19:114–120. Curran WJ, Scott CB. Radiosurgery for glioma patients: Hope or hype? Int J Radiat Oncol Biol Phys 1996; 36:1279–1280. Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: RTOG 83-02. Cancer 1996; 77:1535–1543. Urtasun R, Kinsella T, Farnan N, et al. Survival improvement in anaplastic astrocytoma, combining external beam radiation with halogenated pyrimidines: Final report of RTOG 86-12, phase I-II study. Int J Radiat Oncol Biol Phys 1996; 36:1163–1167. Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: Initial report of Radiation Therapy Oncology Group protocol 90-05. Int J Radiat Oncol Biol Phys 1996; 34:647–654. Curran WJ, Scott CB, Leibel SA. Issues in the use of conventional and altered fractionation radiation therapy for pediatric and adult gliomas. In: Berger M, editor. The Gliomas. Philadelphia: W.B. Saunders; 1996. p. 480–488. Phuphanich S, Scott C, Fischbach A, et al. All-trans-retinoic acid: A phase II radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J Neuro oncol 1997; 34:193–200. Perry JR, DeAngelis LM, Schold SC Jr, et al. Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 1997; 49:912–917. Corn B, Curran W, Shrieve DC, Stereotactic radiosurgery and radiotherapy: New developments and new directions. Semin Oncol 1997; 24:707–714. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37:745–751. Murray K, Scott C, Greenberg H, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastasis: A report of the Radiation Therapy Oncology Group (RTOG) 91-04. Int J Radiat Oncol Biol Phys 1997; 39:571–574. Scott C. Quality-adjusted survival analysis of malignant glioma patients. Control Clin Trials 1997;18:277–285. Choucair A, Scott C, Urtasun R, et al. Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14. Int J Radiat Oncol Biol Phys 1997; 38:9–20. Donahue B, Scott C, Nelson J, et al. Influence of an oligodendroglial component on the survival of patients with analplastic astrocytomas: A report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 1997; 38:911–914. Prados M, Scott C, Rotman M et al. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group (RTOG) trials for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1998; 40:653–659.

8822

Bone

9713

Breast

8806

CNS

Miscellaneous

CNS

NA

CNS

8302

CNS

8612

CNS

9005

CNS

Miscellaneous

CNS

9113

CNS

NA

CNS

Miscellaneous

CNS

Miscellaneous

CNS

9104

CNS

Miscellaneous

CNS

9114

CNS

8302

CNS

7401, 7918, 8302

CNS

(continued) 125

126

I. J. Radiation Oncology

● Biology ● Physics

Volume 51, Number 3, Supplement 2, 2001

Table 1. Manuscripts published (Cont’d) Manuscript reference

Study

Site

Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998; 40:51–55. Prados M, Scott C, Curran W et al. PCV chemotherapy in anaplastic glioma: A retrospective review of Radiation Therapy Oncology Group (RTOG) protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 1999; 17:3389–3395. Prados M, Scott C, Sandler H, et al. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: A preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys 1999; 45:1109–1115. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000; 147:291–298. Coughlin C, Scott C, Langer C, et al. Phase II, two-arm RTOG trial (94-11) of bischloroethylnitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (⬎20 Or ⱕ20 cm2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys 2000; 48:1351–1358. DelRowe J, Scott C, Werner-Wasik M, et al. A single-arm open label phase II study of intravenously administered tirapazamine plus radiation therapy for glioblastoma multiforme. J Clin Oncol 2000; 18:1254–1259. Mehta M, Sanghavi S, Miranpuri S, et al. A multi-center database analysis predicting survival benefit for brain metastases patients treated with radiosurgery. Cancer 2000; 6:408. Murray KJ, Scott C, Zachariah B, et al. Importance of the mini mental status exam in the treatment of patients with brain metastases: A report from the Radiation Therapy Oncology Group protocol 91-04. Int J Radiat Oncol Biol Phys 2000; 48:59–64. Gaspar L, Scott C, Murray K, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001–1006. Corn B, Dolinskas C, Scott C, et al. Strong correlation between imaging response and survival among patients with primary central nervous system lymphoma: A secondary analysis of RTOG studies 83-15 and 88-06. Int J Radiat Oncol Biol Phys 2000; 47:299–303. Fisher B, Scott C, Macdonald D, et al. Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group trial 95-07. J Clin Oncol 2001; 19:1111–1117. Sanghavi S, Miranpuri S, Chappell R, et al. Survival of brain metastases patients treated with radiosurgery and stratified by recursive partitioning analysis: A multi-institutional study. Int J Radiat Onco Biol Phys. In press. Langer C, Paulus R, Ruffer J, et al. Phase II RTOG trial of weekly paclitaxel and conventional exterenal beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys. In press. Flam MS, John MJ, Pajak TF, Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal. Results of a phase III randomized intergroup Study. J Clin Oncol. 1996; 14:2527–2539. John M, Pajak T, Flam M, et al. Dose escalation in chemoradiation for anal cancer: Preliminary results of RTOG 92-08. Cancer J Sci Am 1996; 2:205–211. Minsky BD, Neuberg D, Kelsen DP, et al. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: A preliminary analysis of the Phase II intergroup trial 0122. J Clin Oncol 1996; 14:149–155. Tepper JE, O’Connell MJ, Petroni GR, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114. J Clin Oncol 1997; 15:2030–2039. Al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study (RTOG 85-01, SWOG 8598, NCCTG 884051). J Clin Oncol 1997; 15:277–284. Gaspar LE, Qian C, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): Preliminary toxicity report. Int J Radiat Oncol Biol Ph 1997; 37:593–599. Abrams RA, Pajak TP, Haulk TL, et al. Survival results among patients with alpha petoprotein positive, unresectable hepatocellular carcinoma: Analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J Sci Am 1998; 4: 178–184.

9006

CNS

7918, 8302, 9006, 9404

CNS

9404

CNS

9005

CNS

9411

CNS

9417

CNS

Miscellaneous

CNS

9104

CNS

9104

CNS

8315, 8806

CNS

9507

CNS

Miscellaneous

CNS

9602

CNS

8704

GI

9208

GI

9012

GI

9014

GI

8501

GI

9207

GI

8319, 8823

GI

(continued)

RTOG publications since 1996

127

Table 1. Manuscripts published (Cont’d) Manuscript reference

Study

Site

Kelsen D, Ginsberg R, Pajak T, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Eng J Med 1998; 339:1979–1984. Bonin S, Pajak T, Russell A, et al. Overexperssion of p53 protein and outcome of patients treated with cheomradiation for carcinoma of the anal canal. Cancer 1999; 85:1226–1233. Steele G, Herndon J, Bleday R, et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol 1999; 6:433–441. Streeter O, Martz K, Gaspar L, et al. Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG 85-01? Int J Radiat Oncol Biol Phys 1999; 44:1047–1052. Minsky BD, Neuberg D, Kelsen DP, et al. Final report of intergroup trial 0122 (ECOG PE289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999; 43:517–523. Cooper J, Guo M, Herskovic A, et al. Chemoradiotherapy significantly improves the cure rate of locally advanced esophageal cancer; long-term follow-up of a prospective randomized intergroup trial (RTOG 85-01). JAMA 1999; 281:1623–1627. Kelsen D, Pajak T, Ginsberg R. Treatment of esophageal cancer: Response to 8911 survival by response to CT. N Eng J Med 1999; 340:1685. Russell A, Harris J, Rosenberg P, et al. Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: Long-term results of Radiation Therapy Oncology Group protocol 89-02. Int J Radiat Oncol Biol Phys 2000; 46:313–322. Gaspar LE, Winter K, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy for patients with localized carcinoma of the esophagus (RTOG 9207): Final report. Cancer 2000; 188:988–995. Macdonald J, Smalley S, Benedetti J, et al. Combined modality chemo-radiation therapy improved survival in patients with resected adenocarcinoma of the stomach and gastroesophageal junction. N Eng J Med In press. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of RTOG phase II trial 88-02. J Clin Oncol 1996; 14:119–126. Shipley W. Translational research in bladder cancer. Int J Radiat Oncol Biol Phys 1996; 35: 411–412. Lawton CA, Coleman CN, Buzydlowski JW, et al. Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG protocol 90–20). Int J Radiat Oncol Biol Pys 1996; 36:673–680. Roach M. The role of PSA in the radiotherapy of prostate cancer. Oncology 1996; 10:1143– 1150. Pilepich M, Caplan R, Byhardt R, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of RTOG protocol 85-31. J Clin Oncol 1997; 15:1013–1021. Grignon D, Caplan R, Sarkar F, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 86-10. J Natl Cancer Inst 1997; 89:158–165. Lawton CA, Winter K, Byhardt R, et al. Androgen suppression plus radiation vs. radiation alone for patients with D1 (pN⫹) adenocarcinoma of the prostate (results based on a national prospective randomized trial RTOG 85-31). Int J Radiat Oncol Biol Phys 1997; 38:931–939. Shipley W, Winter K, Kaufman D, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy. Initial results of RTOG 89-03. J Clin Oncol 1998; 16:3576–3583. Asbell SO, Martz KL, Shin KH, et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG 77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 1998; 40:769–782. Vijayakumar S, Winter K, Sause W et al. Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: Results of RTOG 94-12. Int J Radiat Oncol Biol Phys 1998; 40:17–25. Hanks G, Buzydlowski J, Sause W, et al. Ten year outcomes for pathologic node positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys 1998; 40:765–768. Corn B, Winter K, Pilepich M For the Radiation Therapy Oncology Group. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Urology 1999; 54:495–502.

8911

GI

8704

GI

9109

GI

8501

GI

9012

GI

8501

GI

8911

GI

8902

GI

9207

GI

9018

GI

8802

GU GU

9020

GU

9413

GU

8531

GU

8610

GU

8531

GU

8903

GU

7706

GU

9412

GU

7506

GU

8531

GU

(continued)

128

I. J. Radiation Oncology

● Biology ● Physics

Volume 51, Number 3, Supplement 2, 2001

Table 1. Manuscripts published (Cont’d) Manuscript reference

Study

Site

Roach M, Lu J, Pilepich M, et al. Long term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials. J Urol 1999; 161:864–868. Kaufman D, Winter K, Shipley W, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000; 5:471–476. Roach M, Lu J, Pilepich M, et al. Four prognostic subgroups predict long term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000; 47:609–615. Roach M, Lu J, Pilepich M, et al. Predicting long term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000; 47:617–627. Michalski JM, Purdy JA, Winter K. et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000; 46:391–402. Valicenti R, Lu J, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 2000; 18:2740–2746. Pajak T, Clark G, Sargent D, et al. Statistical issues in tumor marker studies. Arch Pathol Lab Med 2000; 124:1011–1015. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000; 355:1491–1498. Bostwick D, Grignon D, Hammond E, et al. Prognostic factors in prostate cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124:995–1000. Lu J Statistical aspects of evaluating treatment and prognostic factors for clinically localized prostate cancer. Semin Urol Oncol 2000; 18:83–92. Dalesio O, van Tinteren H, Peto R, Androgen blockade in prostate cancer (correspondence). Lancet 2000; 356:341–342. Lu J, Pajak T. Statistical power for a long-term survival trial with a time-dependent treatment effect. Control Clin Trials 2000; 21:561–573. Horwitz E, Winter K, Hanks G, et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term versus short-term adjuvant hormones for patients with locally advanced non-metastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49:947–956. Lawton C, Winter K, Murray K, Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49:937–946. Pilepich MK, Winter Fu K, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys In press. John M, Flam M, Caplan R, et al. Final results of a phase II chemoradiation protocol for locally advanced cervical cancer: RTOG 85-15. Gynecol Oncol 1996; 61:221–226. Spanos WJ Jr, Pajak TF, Emami B, et al. Radiation palliation of cervical cancer. J Natl Cancer Inst 1996; 21:127–130. Grigsby P, Lu J, Mutch D, et al. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10. Int J Radiat Oncol Biol Phys 1998; 41:817–822. Grigsby P, Winter K, Wasserman T, et al. Irradiation with or without misonidazole for patients with stages IIIb and IVa carcinoma of the cervix: Final results of RTOG 8005. Int J Radiat Oncol Biol Phys 1999; 44:513–517. Morris M, Eifel P, Lu J, et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: A randomized RTOG clinical trial. N Engl J Med 1999; 340:1137–1143. Peters W, Liu P, Barrett R, et al. Concurrent chemotherapy and pelvic radiation therapy compared to pelvic radiation therapy alone as adjuvant therapy following radical surgery in high-risk early stage cancer of the cervix. J Clin Oncol 2000; 18:1606–1613. Cooper J, Farnan N, Asbell S, et al. Recursive partitioning analysis of 2,105 patients treated in RTOG studies of head and neck cancer. Cancer 1996; 77:1905–1911. Fu KK, Cooper JS, Marcial VA, et al. Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer. Int J Radiat Oncol Biol Phys 1996; 35:425–438.

7706, 7506, 8531, 8610 9506

GU

7706, 7506, 8531, 8610

GU

7706, 7506, 8531, 8610

GU

9406

GU

7506, 7706, 8531, 8610

GU

8610

GU

8610

GU

NA

GU

Miscellaneous

GU

8610

GU

8531

GU

8531, 8610

GU

8531

GU

8610

GU

8515

GYN

8502

GYN

9210

GYN

8005

GYN

9001

GYN

9112

GYN

7619, 7913, 7915, 8313 Miscellaneous

HN

GU

HN (continued)

RTOG publications since 1996

129

Table 1. Manuscripts published (Cont’d) Manuscript reference

Study

Site

Cooper JS, Scott CB, Asbell SO, et al. Comparison of RPA-derived staging and AJCC staging in head and neck cancers based on RTOG data. Radiat Oncol Invest 1996; 4:140–144. Fu KK, Cox JD, Pajak TF. In response to Bentzen and Thames: Regarding dose-response relationships for late radiation effects in the head and neck: Analysis of RTOG 83-13 Trial, Fu et al. IJROBP 1995; 32:577–588. Int J Radiat Oncol Biol Phys 1996; 34:524–525. Al-Sarraf M, Pajak T, Byhardt R, et al. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 1997; 37:777–782. Riese N, Buswell L, Noll L, et al. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial. Int J Radiat Oncol Biol Phys 1997; 39:855–858. Cooper JS: Current and future therapy of nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 1997; 37:973–974. Cooper JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable head and neck tumors based on RTOG 85-03 and 88-24: Targets for postoperative radiochemotherapy? Head and Neck Surg 1998; 20:588–594. Al-Sarraf M, LeBlanc M, Giri P, et al. Chemoradiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer: Phase III randomized intergroup study (0099) (SWOG 8892, RTOG 8817, ECOG 2388). J Clin Oncol 1998; 16:1310–1317. Lee WR, Berkey B, Marcial V, Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998; 42:1069–1075. Spitz MR, Lippman SM, Jiang H Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst 1998; 90:243–245. Vokes E, Pajak T. Enhancing the therapeutic index of concomitant chemoradiotherapy and head and neck cancer. Ann Oncol 1998; 9:471–473. Jacobs JR, Logemann J, Pajak TF, Failure of cricopharyngeal myotomy to improve dysphagia following head and neck cancer surgery. Arch Otolaryngal Head Neck Surg 1999; 125:942– 946. Aref A, Berkey B, Schwade J, et al. The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: Secondary analysis of RTOG 85-03. Int J Radiat Oncol Biol Phys 2000; 47:389–394. Fu K, Pajak T, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy, for head and neck squamous cell carcinomas: First report of RTOG 90-03. Int J Radiat Oncol Biol Phys 2000; 48:7–16. Pignon J, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analysis of updated individual data. Lancet 2000; 355:949–955. Hammond E, Fitzgibbons P, Compton C, et al. College of American Pathologists Conference XXXV: Solid tumor prognostic factors—which, how and so what? Arch Pathol Lab Med 2000; 124:958–965. Cox JD, Fu KK, Pajak T, et al. Radiation Therapy Oncology Group (RTOG) trials for head and neck cancer. RAYS 2000; 25:321–323. Cooper J, Berkey B, Marcial V, et al. Validation of the RTOG recursive partitioning classification for head and neck tumors. Head Neck J In press. Emami B. Three-dimensional conformal radiation therapy in bronchogenic carcinoma. Semin Radiat Oncol 1996; 6:92–97. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: RTOG protocol 91-06. J Clin Oncol 1996; 14:1055–1064. Curran W. New chemotherapy/radiation therapy regimens may improve survival for patients with locally advanced, unresectable non-small cell lung cancer. COPE 1996; Jan/Feb:10–17. Turrisi AT III, It’s about time, or is it: Volume, fractionation, or technique? Int J Radiat Oncol Biol Phys 1996; 36:753–755. Komaki R, Scott C, Lee J, et al. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): Comparison of RTOG 83-11 to RTOG 91-06. Am J Clin Oncol 1997; 20:435–440. Scott C, Sause W, Byhardt R, et al. Recursive partitioning analysis of 1,592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. Lung Cancer 1997; 17(Suppl. 1):S59–S74.

Miscellaneous

HN

8313

HN

8824

HN

8527

HN

NA

HN

8503, 8824

HN

8817

HN

8527

HN

9115

HN

Miscellaneous

HN

8530

HN

8503

HN

9003

HN

6801, 8503

HN

Miscellaneous

HN

Miscellaneous

HN

8527

HN

Miscellaneous

Lung

9106

Lung

8804, 8808, 9015, 9016 Miscellaneous

Lung

8311, 9106

Lung

8311, 8321, 8403, 8407

Lung

Lung

(continued)

130

I. J. Radiation Oncology

● Biology ● Physics

Volume 51, Number 3, Supplement 2, 2001

Table 1. Manuscripts published (Cont’d) Manuscript reference

Study

Site

Komaki R, Scott C, Ettinger D, et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 1997; 38:149–155. Ginsberg R, Cox J, Green M, et al. Consensus report: Staging classification committee. Lung Cancer 1997; 17(Suppl. 1):S11–S13. Komaki R, Scott CB, Sause WT, et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys 1997; 39:537–544. Byhardt RW. An overview of the radiotherapeutic management of non-small cell lung cancer (NSCLC), based on the clinical trials of the radiation Therapy Oncology Group (RTOG). In: Progress in Anti-Cancer Chemotherapy. Hortobagyi G, Khayat P, editors. Paris Blackwell Science; 1997. p. 113–131. Scott CB. Issues in quality of life assessment during cancer therapy. Semin Radiat Oncol 1998; 8(Suppl. 1):5–9. Orton CG, Chungbin S, Klein EE, et al. Study of lung density corrections in a clinical trial RTOG 88-08. Int J Radiat Oncol Biol Phys 1998; 41:787–794. Byhardt R, Scott C, Sause W, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998; 42:469–478. Curran WJ, Wasik-Werner M. Issues in nonoperative management of locally advanced non small cell lung cancer. Oncology 1998; 12 (Suppl. 2):60–66. Werner-Wasik M, Curran WJ. Optimizing nonoperative approaches to locally advanced nonsmall cell lung cancer. Adv Oncol 1998; 13:10–16. Komaki R, Scott C, Byhardt R, et al. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1,547 on four Radiation Therapy Oncology Group (RTOG) studies in operable non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1998; 42:263–267. Werner-Wasik M, Scott C, Graham M, et al. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: A multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys 1999; 44:327–331. Cox J, Scott C, Byhardt R, et al. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): Analysis of Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1999; 43: 505–509. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999; 45:1143–1149. Machtay M, Seiferheld W, Komaki R, et al. Is prolonged survival possible for patients with supraclavicular node metastases in NSCLC treated with chemoradiotherapy? Analysis of the RTOG Experience. Int J Radiat Oncol Biol Phys 1999; 44:847–853. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265–271. Herskovic A, Scott C, Demas W, et al. Accelerated hyperfractionation for bronchogenic cancer—RTOG 92-05. Am J Clin Oncol 2000; 23:207–212. Sause W, Kolesar P, Taylor S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588. Chest 2000; 117:358–364. Werner-Wasik M, Scott C, Cox J, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different surival. Int J Radiat Oncol Biol Phys 2000; 48:1475–1482. Keller S, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small cell lung cancer. N Engl J Med 2000; 343:1217–1222. Glisson B, Scott C, Komaki R, et al. Cisplatin, ifosfamide, oral etoposide and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinioma: Results of RTOG 93-12. J Clin Oncol 2000; 18:2990–2995.

9204

Lung

Miscellaneous

Lung

8808

Lung

Miscellaneous

Lung

Miscellaneous

Lung

8808

Lung

8804, 8808, 9015, 9106

Lung

Miscellaneous

Lung

Miscellaneous

Lung

8311, 8321, 8403, 8407

Lung

8311, 8808, 9015, 9106

Lung

Miscellaneous

Lung

Miscellaneous

Lung

Miscellaneous

Lung

8815

Lung

9205

Lung

8808

Lung

Miscellaneous

Lung

9105

Lung

9312

Lung

(continued)

RTOG publications since 1996

131

Table 1. Manuscripts published (Cont’d) Manuscript reference

Study

Site

Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93:605–618. Schiller J, Adak S, Foins B, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer on E4592: A laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 2001; 19:448–457. Emami B, Scott C, Byhardt R, et al. The value of regional nodal radiotherapy (dose/volume) in the treatment of unresectable non-small cell lung cancer: An RTOG analysis. Lung Cancer. In press. Cox J, Scott CB, Smith C, et al. Dose escalation for non-small cell carcinoma of the lung before 3D conformal radiation therapy: Long-term observations of normal tissues from RTOG protocol 83-11. In: Morney E, Van Houtte P, editors. Treatment optimization for lung cancer: From classical to innovative procedures. Paris: Elsevier; 1998. p. 151–156. Emami B, Scott C, Perez C, et al. Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the treatment of recurrent or persistent human tumors: A prospectively controlled randomized study by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1996; 34:1097–1104. Myerson RJ, Scott CB, Emami B, et al. A phase I/II study to evaluate radiation therapy and hyperthermia for deep-seated tumors: A report of RTOG 89-08. Int J Hyperthermia 1996; 12:449–459. Owen J, Grigsby P, Caldwell T, et al. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodological pilot studies of Radiation Therapy Oncology Group (RTOG) studies 90-03 and 91-04. Int J Radiat Oncol Biol Phys 2001; 49:633–639. Wasserman T, Bruner D, Scott C. Radiation Therapy Oncology Group (RTOG). J Natl Cancer Inst Monog 1996; 20:81–82. Konski A, Grigsby P. Economic Analyses: New endpoints for clinical trials. Int J Radiat Oncol Biol Phys 1996; 35:847–848. Scott C, Wasserman T. When is a negative study not negative? Int J Radiat Oncol Biol Phys 1997; 39:859–861. Chamberlain RM, Porter A, Vijayakumar S, et al. Sociodemographic analysis of patients in Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 1998; 40: 9–15. Curran WJ Jr. Radiation-induced toxicities: The role of radioprotectants. Semin Radiat Oncol 1998; 8(Supl. 1):2–4. Mehta MP. Protection of normal tissues from the cytotoxic effects of radiation therapy: Focus on amifostine. Semin Radiat Oncol 1998; 8(Supl, 1):14–16. Cleeland C, Janjan NA, Scott CB, et al. Cancer pain management by radiotherapists: A survey of Radiation Therapy Oncology Group physicians. Int J Radiat Oncol Biol Phys 2000; 47: 203–208. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47:13–47.

9101

Lung

9409

Lung

7811, 7917, 8311, 8407

Lung

8311

IGRT

8419

NSS

8908

NSS

9003, 9104

Multi

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Multi

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Abbreviations: CNS ⫽ central nervous system; NA ⫽ not applicable; GI ⫽ gastrointestinal; GU ⫽ genitourinary; GYN ⫽ gynecology; HN ⫽ head and neck; IGRT ⫽ image-guided radiotherapy; NSS ⫽ not site specific.

132

I. J. Radiation Oncology

● Biology ● Physics

Volume 51, Number 3, Supplement 2, 2001

Table 2. Abstracts published Abstract reference

Study

Site

Kraybill W, Spiro I, Harris J, et al. Radiation Therapy Oncology Group (RTOG) 95-14: A phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in high risk (HR), high grade, soft tissue sarcomas (STS) of the extremities and body wall—A preliminary report. Proceedings from the American Society Clinical Oncology (ASCO), San Francisco, CA, J Clin Oncol 2001; 20:348a. Kuske RR, Wilenzick RM, Hanson WF, et al. Quality assessment and quality control for interstitial brachytherapy in a cooperative group trial. Proceedings of the Radiological Society of North America (RSNA), Chicago, IL, 1997. Fisher J, Scott C, Stevens R, et al. Randomized study comparing best supportive care to biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-13. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, TX. Int J Radiat Oncol Biol Phys 1999; 45:233–234. Scott C, Paulus R, Stevens R, et al. Is radiation-induced skin toxicity of the breast associated with reduced quality of life: Report of RTOG 97-13. Proceeding from International Society of Quality of Life Research (ISOQOL). Qual Life Res 1999; 8:571. Fisher J, Scott C, Stevens R. A study comparing the efficacy of the Oncology Nursing Society radiation therapy patient acute toxicity scale for breast to the Radiation therapy Oncology Group acute skin toxicity scale in measuring acute skin toxicity in women undergoing breast irradiation. Oncology Nursing Society, San Antonio, TX. Oncol Nursing Forumology 2000; 27:351 Fisher J, Scott C, Stevens R, et al. Phase III randomized study comparing best supportive care to Biafine as a prophylactic agent for radiation-induced skin toxicity in women undergoing breast irradiation: RTOG 9713. Great Lakes Cancer Nursing Conference Great Lakes. 2000. Hughes K, Schnaper L, Berry D, et al. Comparison of lumpectomy plus tamoxifen with and without radiotherapy (RT) in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER⫹) breast carcinoma. Proceedings of the American Society for Clinical Oncology(ASCO), San Francisco, CA. J Clin Oncol 2001; 20:24a. Hanson W, Martin E, Kuske RR, et al. Dose specification and quality assurance of RTOG protocol 95-17, a cooperative group study of 192Ir breast implants as sole therapy. American Association Physicians in Medicine (AAPM), Salt Lake City, UT. In press. Nelson J, Petito C, Scott C, et al. High cell density and nuclear pleomorphism do not predict shortened survival in oligodendroglial tumors: Report from Radiation Therapy Oncology Group (RTOG) study 83-02. American Association Neuropathologists, Vancouver BC. J Neuropathol Exper Neurol 1996; 55:638. Scott C. Is there a gold standard for assessing quality of life in patients with malignant brain tumors? International Society of Quality of Life Research (ISOQOL), Manila, Philippines, Qual Life Res 1996; 6:425–426. Murray K, Scott C, Greenberg H, et al. A randomized phase III study of accelerated hyperfractionation versus standard fractionation in patients with unresected brain metastasis: A report of Radiation Therapy Oncology Group (RTOG) 91-04. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:193. Curran W, Scott C, Yung W, et al. No survival benefit of hyperfrationated radiotherapy (RT) to 72.0 Gy & carmustine versus standard RT & carmustine for malignant glioma patients: Preliminary results of RTOG 90-06. Proceedings of the American Society for Clinical Oncology (ASCO), Philadelphia, PA, J Clin Oncol 1996; 15:154. Curran WJ, Scott CB, Yung WA, et al. Imaging response is highly predictive of survival of malignant glioma patients treated with standard or hyperfractionated RT and carmustine in RTOG 90-06. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:160. Donahue B, Scott C, Nelson J, et al. Influence of an Oligodendrogliomal component on the survival of patients with anaplastic astrocytomas: A report of Radiation Therapy Oncology Group 83-02. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:161. Nelson J, Petito C, Scott C, et al. Glioblastoma with oligodendroglial features GBM-OL: Report from Radiation Therapy Group (RTOG) trial 83-02. United States/Canadian Academy of Pathology, Canada. Lab Invest 1996; 74:141A. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:160.

9514

Bonr

9517

Breast

9713

Breast

9713

Breast

9713

Breast

9713

Breast

9702

Breast

9517

Breast

8302

CNS

CNS 9104

CNS

9006

CNS

9006

CNS

8302

CNS

8302

CNS

9006

CNS

(continued)

RTOG publications since 1996

133

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Choucair A, Scott C, Movsas B, et al. Prognostic factors in malignant astrocytoma (MA): Data from RTOG 91-14. Twelfth International Conference on Brain Tumor, Oxford, United Kingdom. J Neurooncol 1997; 35:513. Coughlin C, Scott C, Langer C, et al. Phase II tumor volume-influenced dose escalation of accelerated hyperfractionated RT to 64.0 & 70.4 Gy with BCNU for newly diagnosed radiosurgery-ineligible glioblastoma multiforme (GBM) patients (RTOG 94-11). Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orland, FL. Int J Radiat Oncol Biol Phys 1997; 39:270. DelRowe J, Scott C, Bahary J, et al. A single-arm, open label, phase II study of intravenously administered tirapazamine plus radiation therapy for glioblastoma multiforme (GBM)—RTOG 94-17. Proceedings of the American Society for Clinical Oncology (ASCO), Denver, CO. J Clin Oncol 1997; 16:385a. MacDonald D, Kolesar P, Coughlin C, et al. A phase I study of topotecan plus cranial radiation for glioblastoma multiforme: A report of Radiation Therapy Oncology Group (RTOG) study 95-07. Proceedings of the Society for Neuro-Oncology, Charlottesville, VA. Neurooncology Booklet 1997. Prados M, Scott C, Phillips T, et al. Phase III randomized study of radiotherapy plus PCV with or without BUdR for the treatment of anaplastic astrocytoma: RTOG 94-04. Proceedings of the Society for Neuro-Oncology, Charlottesville, VA. Neurooncology Booklet 1997. Kolesar P, Scott C, Phillips T, et al. Prognostic significance of post radiation tumor response in brain metastases: Analysis of Radiation Therapy Oncology Group (RTOG) database. Proceedings of the Society for Neuro-Oncology, Charlottesville, VA. Neurooncology Booklet 1997. Corn B, Dolinskas C, Scott C, et al. Strong correlation between imaging response and survival among patients with primary central nervous system lymphoma: A secondary analysis of RTOG studies 83-15 and 88-06. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:325. Corn B, Dolinskas C, Scott C, et al. Strong correlation between imaging response and survival among patients with primary central nervous system lymphoma: A secondary analysis of RTOG studies 83-15 and 88-06. Proceedings of the Society for Neuro-Oncology, Charlottesville, VA. Neurooncology Booklet. 1997. MacDonald D, Kolesar P, Coughlin C, et al. A phase I study of Topotecan plus cranial radiation for glioblastoma multiforme: A report of Radiation Therapy Oncology Group (RTOG) study 95-07. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys. 1997; 39:271. Prados M, Scott C, Phillips T, Phase III randomized study of radiotherapy plus PCV with or without BUdR for the treatment of anaplastic astrocytoma: RTOG 94-04 Interim Report. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL, Int J Radiat Oncol Biol Phys 1997; 39:138. Schultz C, Whittaker M, Kolesar P, Incidence of EBV infection in primary CNS lymphoma occurring in immunocompetent patients treated on RTOG 83-15 and 88-06. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:176. Schultz C, Whittaker M, Kolesar P, et al. EBV Infection in immunocompetent patients with primary CNS lymphoma treated on RTOG 83-15 and 88-06. Proceedings of the Society for Neuro-Oncology, Charlottesville, VA. NeuroOncology Booklet 1997. Carde P, Timmerman B, Koprowski D, et al. Gadolinium-texaphyrin (Gd-Tex) radiation sensitizer: Improved survival in a phase Ib/II trial in patients with brain metastases. Proceedings of the American Society for Clinical Oncology (ASCO). J Clin Oncol 1998; 17: 379a. DelRowe J, Scott C, Werner-Wasik M, et al. A single-arm open label phase II study of intravenously administered Tirapazamine for glioblastoma multiforme (GBM): An RTOG study. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:266. Nelson J, Scott C, Constine L, et al. Alzheimer related lesions (ARL) and neural morbidity in glioblastoma (GBM) patients: Data from Radiation Therapy Oncology Group (RTOG) glioma trials. US/Canadian Pathology, Boston, MA. Lab Invest Mod Pathol 1998; 78:161A. Prados M, Scott C, Curran W, et al. PCV chemotherapy in anaplastic glioma: A retrospective review of Radiation Therapy Oncology Group (RTOG) protocols comparing survival with BCNU or PCV adjuvant chemotherapy. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:197.

9114

CNS

9411

CNS

9417

CNS

9507

CNS

9404

CNS

7916, 8905

CNS

8315, 8806

CNS

8806, 8315

CNS

9507

CNS

9404

CNS

8315, 8806

CNS

8806, 8315

CNS CNS

9417

CNS

Miscellaneous

CNS

7918, 8302, 9006, 9404

CNS

(continued)

134

I. J. Radiation Oncology

● Biology ● Physics

Volume 51, Number 3, Supplement 2, 2001

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Ruffer J, Scott C, Langer C, et al. A phase II trial of weekly paclitaxel and conventional radiotherapy for supratentorial glioblastoma multiforme: RTOG 96-02. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:265. Scott C, Curran W, Yung W, et al. Long term results of RTOG 9006: A randomized trial of hyperfractionated radiotherapy (RT) to 72.0 Gy & carmustine vs. standard RT & carmustine for malignant glioma patients with emphasis on anaplastic astrocytoma (AA) patients. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:401a. Shaw E, Arusell R, Scheithauer B, et al. A prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a NCCTGRTOG-ECOG study. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:401a. Shaw E, Scott C, Souhami L, et al. Update of Radiation Therapy Oncology Group (RTOG) protocol 90-05: Single dose radiosurgical treatment of recurrent brain tumors. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:196. Shaw E, Arusell R, Scheithauer B, et al. A prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a NCCTGRTOG-ECOG study. Soc Neuro Oncol, San Francisco, CA. J Clin Oncol 1998:401a. Shaw E, Scott C, Souhami L, et al. Update of Radiation Therapy Oncology Group (RTOG) protocol 9005: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases. Proceedings of the Society of Neuro-oncology, San Francisco, CA. 1998. Murray K, Scott C, Zachariah B, et al. Importance of the mini mental status exam (MMSE) in the treatment of patients with brain metastases: A report from the Radiation Therapy Oncology Group protocol 91-04. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:261. Gaspar L, Scott C, Murray K, et al. Validation of the RTOG recursive partitioning analysis (RPA) Classification for Brain Metastases. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:260. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Impact of linear accelerator (LINAC) versus gamma knife (GK) radiosurgery on efficacy and toxicity—dose conformity and heterogeneity. ISRS 4th World Congress, 1998. Sanghavi S, Mehta M. Multi-institutional survival analysis of brain metastases patients treated with radiosurgery, stratified by RTOG RPA classification. Proceedings of the 85th Scientific Assembly and Meeting of Radiological Society of North America, Chicago, IL, December, 1999. Sanghavi S, Miranpuri S, Chappell R, et al. Multi-institutional analysis of prognostic factors and survival outcome for radiosurgery treated patients with brain metastases, Stratified by RTOG RPA Classification. Proceedings of LINAC Radiosurgery Annual Science Meeting, Orlando, FL, 1999. p. 37. Wasserman T, Scott C, Shaw E, et al. A phase II trial of the radiosensitizer: Etanidazole (Sr2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Protocol 95-02). Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, TX. Int J Radiat Oncol Biol Phys 1999; 45:272. Gaspar L, Scott C, Murray K, et al. RTOG recursive partitioning analysis (RPA) classification for brain metastases: A valid staging system. Proceedings of the American Radium Society, Hapuna Beach, Hawaii. 1999. Sanghavi S, Miranpuri S, Chappell R, et al. Multi-institutional survival analysis of brain metastases patients treated with radiosurgery, stratified by RTOG RPA classification. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, TX. Int J Radiat Oncol Biol Phys. 1999; 45:171. DeAngelis L, Seiferheld W, Schold S, et al. Combined modality treatment of primary central nervous system lymphoma (PCNSL): RTOG 93-10. Proceedings of the American Society for Clinical Oncology (ASCO), Atlanta, GA. J Clin Oncol 1999; 18:140a. Langer C, Paulus R, Ruffer J, et al. Phase II RTOG trial of weekly paclitaxel (TAX) and conventional external beam radiation therapy (EBRT) for supratentorial glioblastoma multiforme (GBM). Proceedings of the American Society for Clinical Oncology (ASCO), Atlanta, GA. J Clin Oncol 1999; 18:139a.

9602

CNS

9006

CNS

9110

CNS

9005

CNS

9110

CNS

9005

CNS

9104

CNS

9104

CNS

9005

CNS

CNS

CNS

9502

CNS

9104

CNS CNS

9310

CNS

9602

CNS

(continued)

RTOG publications since 1996

135

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Andrews DW, Scott C, Sperduto P, et al. Preliminary analysis of RTOG 95-08: A phase III prospective randomized trial comparing whole brain irradiation alone versus whole brain irradiation plus stereotactic radiosurgery for patients with two or three brain metastases. Congress of Neurological Surgeons, San Antonio, TX, 2000. Regine W, Scott C, Murray K, et al. Neurocognitive outcome in brain metastasis patients treated with accelerated fractionation (AF) vs. accelerated hyperfractionation (AH) whole brain radiotherapy (WBRT): An analysis from Radiation Therapy Oncology Group (RTOG) study 91-04. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:158–159. Shaw E, Scott C, Stea B, et al. Survival improvement with RSR13 plus cranial radiation therapy (RT) in patients (Pts) with brain metastases: Comparison to the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) brain metastases database (BMD). Proceedings of the American Society for Clinical Oncology (ASCO), New Orleans, LA. J Clin Oncol 2000; 19:159a. Shaw E, Scott C, Stea B, et al. RSR13 plus cranial radiation therapy improves survival in patients with brain metastases compared to the RTOG recursive partitioning analysis brain metastases database: Update of a phase II trial. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:203. Sperduto P, Scott C, Andrews D, et al. Preliminary report of RTOG 95-08: A phase III trial comparing whole brain irradiation alone versus whole brain irradiation plus stereotactic radiosurgery for patients with two or three unresected brain metastases. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:113. Schultz C, Scott C, DeAngelis L, et al. Radiation therapy (RT) alone vs. pre-RT chemotherapy (CTX) for the treatment of primary CNS lymphoma (PCNSL): Aged matched survival analysis of RTOG 83-15 and RTOG 93-10. Proceedings of the American Society for Clinical Oncology (ASCO), New Orleans, LA. J Clin Oncol 2000; 19:159a. Yung WA, Seiferheld W, Donahue B, et al. A RTOG (Radiation Therapy Oncology Group) phase II study of conventional radiation therapy plus thalidomide followed by thalidomide post XRT for supratentorial glioblastoma. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:52a. Scott C, Seiferheld W, Prados M, et al. Is time to tumor progression (TTP) an appropriate endpoint for clinical trials in anaplastic astrocytomas (AA)? Analysis of Radiation Therapy Oncology Group (RTOG) study 9404. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:51a. Brown P, Buckner J, Brown C, et al. The effects of radiation on cognitive function in patients with low-grade glioma. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:58a. Bonin S, Qian C, Russell A, et al. Overexpression of p53 protein is associated with decreased local disease-free survival in patients treated with chemoradiation for anal canal cancer: A report of RTOG 87-04. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:210. Al-Sarraf M, Martz K, Herskovic A, et al. Superiority of chemo-radiotherapy (CT-RT) vs. radiotherapy (RT) in patients with esophageal cancer: Final report of an intergroup randomized and confirmed study. Proceedings of the American Society for Clinical Oncology (ASCO), Philadelphia, PA. J Clin Oncol 1996; 15:206. John M, Pajak T, Kreig R, et al. Dose escalation without split-course chemoradiation for anal cancer: Results of a phase II RTOG study. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:203. Steele J, Herndon J, Burgess A, et al. Sphincter sparing treatment for distal rectal adenocarcinoma: A phase II intergroup study. Proceedings of the American Society for Clinical Oncology (ASCO), Denver, CO. J Clin Oncol 1997; 16:256a. Kelsen D, Ginsberg R, Qian C, et al. Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer: A preliminary report on Intergroup study 113 (RTOG 89-11). Proceedings of the American Society for Clinical Oncology (ASCO), Denver, CO. J Clin Oncol 1997; 16:276a. John M, Flam M, Berkey B, et al. 5 year results and analyses of a phase III randomized RTOG/ ECOG chemoradiation protocol for anal cancer. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:258a.

9508

CNS

9104

CNS

7918, 8528, 8905, 9104

CNS

7918, 8528, 8905, 9104

CNS

9508

CNS

8315, 9310

CNS

9806

CNS

9404

CNS

Miscellaneous

CNS

8704

GI

8501

GI

9208

GI

9109

GI

8911

GI

8704

GI

(continued)

136

I. J. Radiation Oncology

● Biology ● Physics

Volume 51, Number 3, Supplement 2, 2001

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Russell A, Pajak T, Rosenberg P, et al. Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: Long term results of a clinical cooperative group protocol RTOG 8902. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:162. Gaspar LE, Winter K, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): final report. Proceedings of the American Radium Society Meeting, Monte Carlo, Monaco, May 2–6. 1998. p. 52–53. Martenson J, Willett C, Sargent D, et al. A phase III study of adjuvant radiation therapy (RT), 5-flouorouraoil (5-FU), and levamisole (LEV) vs 5-FU and LEV in selected patients with resected high risk colon cancer: Initial results of INT 0130. Proceedings of the American Society for Clinical Oncology (ASCO), Atlanta, GA. J Clin Oncol 1999; 18:235a. Flam M, Pajak T, Haller D, et al. The role of mitomycin in combination with 5-fluorouracil and radiotherapy in the definitive nonsurgical treatment of edipermoid carcinoma of the anal canal: 5 year updated results of a phase III randomized intergroup study RTOG 8704/ECOG 1289. American Radium Society, Hapuna Beach, Hawaii. ARS Meeting Book 1999. p. 26. Flam MS, Pajak TF, Haller D, et al. The role of mitomycin in combination with 5-fluorouracil and radiotherapy in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: 5 year updated results of a phase III randomized study (RTOG 8704/ECOG 1289). Japan/US Cancer Therapy Symposium, Hiroshima, Japan. JUCTS Meeting Book. 1999. p. 63. Ginsberg R, Berkey B, Kelsen D, et al. Surgery for esophageal carcinoma: Lessons to be learned from a recently completed RTOG trial. Proceedings of the American Surgical Meeting, 1999. Sheahan D, Guo M, Kelsen D, Extranodal extension (ENE) in esophageal cancer—A significant prognostic factor: National intergroup study INT 0113/RTOG 89-11. US Canadian Academy of Pathology. Mod Pathol 1999; 12:84A. Gaspar L, Winter K, Kocha W, et al. Swallowing function and weight change observed in a phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 9207). American Radim Society, London, England, April 1–5, 2000. Proceedings of the American Radium Society 2000. p. 16. MacDonald J, Smalley S, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and GE junction: Results of intergroup study INT-0116 (SWOG 9008). Proceedings of the American Society for Clinical Oncology (ASCO), New Orleans, LA. J Clin Oncol 2000; 19:1a. Minsky B, Berkey B, Kelsen D, et al. Preliminary results of intergroup INT 0123 randomized trial of combined modality therapy (CMT) for esophageal cancer: Conventional vs. high dose radiation therapy. Proceedings of the American Society for Clinical Oncology (ASCO), New Orleans, LA. J Clin Oncol 2000; 19:239a. Tepper J, O’Connell M, Niedzwiecki D, et al. Final report of INT 0114—Adjuvant therapy in rectal cancer: Analysis by treatment, stage and gender. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:123a. Grignon D, Pajak T, Hammond E, et al. Application of the Gleason grading system: A comparison of institutional and central review grading using RTOG protocols 85-31 and 86-10. United States–Canadian Academy of Pathology, Washington, DC. Mod Pathol 1996; 9:73A. Grignon D, Won M, Hammond E, et al. DNA content as a prognostic indicator in prostate cancer (PCA): A study based on RTOG protocol 86-10. United States and Canadian Academy of Pathology, Washington, DC. Mod Pathol 1996; 9:74A. Hanks GE, Buzydlowski J, Perez CA, et al., The ten year outcome of pathologic and imaging node positive patients treated with irradiation in RTOG 75-06. Proceedings of the American Urological Association. J Urol 1996. Lawton CA, Pajak TF, Byhardt R, et al. Androgen suppression plus radiation vs. radiation alone for patients with D1 (pN⫹) adenocarcinoma of the prostate (results based on a national prospective randomized trial RTOG 85-31). Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:228. Michalski JM, Purdy JA, Harms WB Sr, et al. Quality assurance of 3-D conformal radiation therapy for a cooperative group trial—RTOG 3D QA center initial experience. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:161. Vijayakumar S, Winter K, Sause W, et al. African-American (AA) men with local-regional prostate cancer (PC) present with higher prostate specific antigen (PSA) levels than whites: Results of RTOG 94-12. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:305.

8902

GI

9207

GI

9203

GI

8704

GI

8704

GI

8911

GI

8911

GI

9207

GI

9018

GI

9405

GI

9014

GI

8610, 8531

GU

8610

GU

7506

GU

8531

GU

9406

GU

9412

GU

(continued)

RTOG publications since 1996

137

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Shipley WU, Winter K, Lee R, et al. Initial results of RTOG 89-03: A phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:155. Grignon D, Pajak T, Winter K, et al. Central review vs. institutional Gleason grading and its impact on phase III clinical trial analysis: A review of RTOG protocol 85-31. United States and Canadian Academy of Pathology Meeting, Toronto, Canada. Mod Pathol 1997; 10:77a. Shipley WU. RTOG clinical trials in locally advanced prostate cancer: Combined androgen suppression/radiotherapy improves progression-free survival. First Sonoma Conference, Sonoma, CA. Oncol News Int 1997; 6:19–20. Winter K, Grignon D, Pajak T, et al. Subjective pathology tumor grading: Impact on design and analysis of Radiation Therapy Oncology Group (RTOG) prostate trial 85-31. Proceedings of the Society for Clinical Trials and International Society for Clinical Biostatistics, Boston, MA. Control Clin Trials 1997; 18:1865–1875. Winter K, Grignon D, Pajak T, et al. The need for central pathology tumor grading in prostate cancer using Radiation Therapy Oncology Group (RTOG) 85-31. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:219. Shipley W, Winter K, Kaufman D, et al. An RTOG phase III trial (#89-03) of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:311a. Bruner D, Scott C, McGowan D, et al. Validation of the sexual adjustment questionnaire (SAQ) in prostate cancer patients enrolled On Radiation Therapy Oncology Group (RTOG) studies 90-20 and 94-08. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:202. Bruner D, Scott C, McGowan D, et al. Factors influencing sexual outcomes in prostate cancer (PC) patients enrolled on Radiation Therapy Oncology Group (RTOG) studies 90-20 and 9408. Proceedings of the International Society for Quality for Quality of Life Research (ISOQOL), Baltimore, MD. Qual Life Res 1998; 7:575. Corn B, Winter K, Pilepich M. Does androgen suppression enhance the efficacy of post-operative irradiation: A secondary analysis of RTOG 85-31. San Diego, CA: American Urology Association (AUA); 1998. Cox J, Lu J, Pilepich M, et al. Does hormone therapy influence the risk of late effects in normal tissues irradiated for carcinoma of the prostate? Data from prospective trials of the Radiation Therapy Oncology Group (RTOG) Monaco: American Radium Society (ARS), Monaco; 1998. Hammond E, Lu J, Doggett R, et al. Microvessel density in prostatic biopsies in a phase III Trial (RTOG 86-10). United States and Canadian Academy of Pathology, Boston, MA. Lab Invest Mode Pathol 1998; 11:74A. Lu J, Pajak T, Winter K. Statistical power for a long term survival trial for an elderly population. Society for Clinical Trials, Atlanta, GA. Control Clin Trials 1998; 19:77S–78S. Michalski J, Purdy J, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:142. Pilepich M, Winter K, Fu K, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial of androgen depravation before and during radiotherapy in locally advanced carcinoma of the prostate. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:308a. Pilepich M, Winter K, Fu K, et al. Phase III radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:177. Roach M, Lu J, Pilepich M, et al. Long term survival in 1500 men treated for prostate cancer with radiotherapy alone (XRT): Based on Radiation Therapy Oncology Group (RTOG) protocols 7706, 7506, 8531 and 8610. San Diego, CA: American Urology Association (AUA), 1998. Roach M, Lu J, Pilepich M, et al. Four prognostic subgroups predict survivals for men treated for prostate cancer with radiotherapy alone: Based on Radiation Therapy Oncology Group (RTOG) 7706, 7506, 8531 & 8610. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:312a.

8903

GU

8531

GU

8610, 9202

GU

8531

GU

8531

GU

8903

GU

9408, 9020

GU

9020, 9408

GU

8531

GU

7506, 7706, 8307, 8531

GU

8610

GU

8531

GU

9406

GU

8610

GU

8610

GU

7706, 7506, 8531, 8610

GU

7706, 7506, 8531, 8610

GU

(continued)

138

I. J. Radiation Oncology

● Biology ● Physics

Volume 51, Number 3, Supplement 2, 2001

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Roach M, Lu J, Pilepich M, et al. Predicting survival, and the role of androgen suppressive therapy (AST): Radiation Therapy Oncology Group RTOG phase III randomized prostate cancer trials. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:177. Shipley W, Winter K, Kaufman D, et al. Initial results of RTOG 95-06: A phase I/II trial of transurethral surgery and fractionated twice-daily radiation with concurrent cisplatin and 5fluorouracil followed either by selective bladder preservation or cystectomy for patients with muscle-invading bladder cancer. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, TX. Int J Radiat Oncol Biol Phys 1999;45: 222. Hammond EH, Grignon DJ, Lu J, et al. Multiple tumor marker analysis in a prostate clinical trial population: RTOG 86-10. Dallas: American Urogical Association; 1999. Horwitz E, Winter K, Hanks G, et al. Long-term outcome for patients with locally advanced nonmetastatic prostate cancer treated with adjuvant hormones and radiation therapy versus radiation therapy alone: subset analysis of RTOG 85-31 and 86-10. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, TX. Int J Radiat Oncol Biol Phys 1999; 45:220–221. Lawton C, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen deprivation following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Proceedings of the American Society for Clinical Oncology (ASCO), Atlanta, GA. J Clin Oncol 1999; 18:311a. Scott C, Roach M, Lawton C, et al. Q-Twist analysis for prostate cancer treated with radiation therapy with or without hormonal therapy: Rtog 86-10. Proceedings of the International Quality of Life Research (ISOQOL). Quality Life Res 1999; 8:568. Valicenti RK, Lu J, Grignon D, et al. Radiation dose-response is Gleason score dependent on the Radiation Therapy Oncology Group prostate cancer trials. Proceedings of the American Society for Clinical Oncology (ASCO), Atlanta, GA. J Clin Oncol 1999; 18:311a. Anderson P, Winter K, Hanks G, et al. Gleason score 4 ⫹ 3 prostate cancer patients have worse bNED outcome compared to Gleason score 3 ⫹ 4 treated with radiation therapy alone: Subset analysis of RTOG 85-31 and 86-10. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:205– 206. Hanks G, Lu J, Machtay M, et al. RTOG protocol 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proceedings of the American Society for Clinical Oncology (ASCO), New Orleans, LA. J Clin Oncol 2000; 19:327a. Hanks G, Lu J, Machtay M, et al. RTOG protocol 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:112. Jimenez R, Lu J, Russell A, et al. Perineural invasion as a prognostic marker in patients treated by radiation therapy (RT): A Radiation Therapy Oncology Group (RTOG) study. United States and Canadian Pathology, New Orleans, LA. J US Can Acad Pathol 2000; 13:113A. Lu J. The design of survival clinical trial with an intermediate event. Society for Clinical Trials, Toronto, Canada. Control Clin Trials 2000; 21:49S. Michalski J, Winter K, Purdy J, et al. Update of toxicity following 3D radiation therapy for prostate cancer on RTOG 94-06. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:228. Pilepich M, Winter K, Byhardt R, et al. Androgen ablation adjuvant to defintive radiotherapy in carcinoma of the prostate: Year 2000 update of RTOG phase III studies 86-10 and 85-31. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:169. Roach M, Lu J, Pilepich M, et al. Race is not an independent predictor of disease specific long term survival among men treated for prostate cancer on Radiation Therapy Oncology Group (RTOG) trials. Atlanta, GA: American Urological Associon (AUA); 2000. Roach M, Winter K, Michalski J, et al. Mean dose of radiation to the bulb of the penis correlates with risk of impotence at 24 months: Preliminary analysis of Radiation Therapy Oncology Group (RTOG) phase I/II dose escalation trial 94-06. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:316.

7706, 7506, 8531, 8610

GU

9506

GU

8610

GU

8531, 8610

GU

8531

GU

8610

GU

7506, 7706, 8531, 8610

GU

8531, 8610

GU

9202

GU

9202

GU

8610

GU GU

9406

GU

8531, 8610

GU

7506, 7706, 8531, 8610

GU

9406

GU

(continued)

RTOG publications since 1996

139

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Shipley W, Lu J, Pilepich M, et al. Neo adjuvant hormone treatment does not compromise the benefits of subsequent androgen suppression with patients in prostate cancer who fail initial radiation therapy: A secondary analysis of the RTOG phase III trial 86-10. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:169–170. Jimenez R, Lu J, Mesic J, et al. Mitotic figures as a prognostic marker in prostate cancer (PCa) patients treated with radiation therapy: A Radiation Therapy Oncology Group (RTOG) study. Proceedings of the United States Canadian Academy of Pathology, Atlanta, GA. Mod Path 2001; 112A. Ryu J, Winter K, Michalski J, et al. Interim report of toxicity from 3D conformal radiation therapy (3DCRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:182a. Shipley W, Heydon K, Pilepich M, et al. A secondary analysis of RTOG 86-10: Does the extent of progression at the time of initiating salvage hormone therapy influence survival in patients with prostate cancer who failed initial treatment with irradiation? Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:182a. Gillin M, Dunning B, Lawton C, et al. Initial physics review of the RTOG 98-05 prostate brachytherapy protocol. Salt Lake City; American Association of Physician in Medicine (AAPM): In press. Grigsby P, Lu J, Mutch D, et al. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:208. Keys H, Bundy B, Stehman F, et al. Adjuvant hysterectomy after radiation therapy reduces detection of local recurrence. New York: Proceedings of American Radium Society; 1997. Grigsby P, Winter K, Wasserman T, et al. Radiotherapy with or without misonidazole for patients with stages IIIb and IVa carcinoma of the cervix: Final results of RTOG 80-05. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:149. Peters W, Liu P, Barrett R, et al. Cisplatin: 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenactomy: Report of a phase III intergroup study. Proceedings of the Society of Gynecologic Oncologists, 1999. No. 1. Grigsby P, Heydon K, Mutch D, et al. Long-term follow-up of RTOG 92-10: Cervical cancer with positive para-aortic lymph nodes. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000;48:212. Al-Sarraf M, Pajak T, Byardt R, et al. Concurrent cisplatin and post-operative radiotherapy (RT) in patients (pts) with stage IV and/or positive margins head and neck cancers: RTOG Study 88-24. Sixth International Congress on Anti-Cancer Treatment, Paris, France. Proc Am Assoc Cancer Res 1996; 37:171. Al-Sarraf M, LeBlanc M, Giri P, et al. Superiority of chemo-radiotherapy (CT-RT) vs. radiotherapy (RT) in patients (Pts) with locally advanced nasopharyngeal cancer (NPC): Preliminary results of intergroup (0099) (SWOG 8892, RTOG 88-17, ECOG 2388) randomized study. Proceedings of the American Society for Clinical Oncology (ASCO), Philadelphia, PA. Proc Am Soc Clin Oncol 1996; 15:313. Giri PS, LeBlanc M, Al-Sarraf M, et al. Improved survival with chemotherapy and radiation therapy versus radiation therapy alone in advanced nasopharyngeal cancer: Preliminary results of an intergroup randomized trial—INT 0099, SWOG 8892, RTOG 8817, ECOG 2388. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:162. Al-Sarraf M, Pajak T, Laramore G, et al. Radiotherapy (RT) vs. chemotherapy (CT) followed by RT in resected and negative margins head and neck cancers (HNC). Intergroup Study 0034: Final analysis. Proceedings of the American Society for Clinical Oncology (ASCO), Denver, Co. J Clin Oncol 1997; 16:392a. Ensley J, Laramore G, Pajak T, et al. DNA content parameters in advanced resectable squamous cell carcinomas of the head and neck (SCCHN): Analysis of INT 0034, a RTOG (85-03) administered head and neck cancer intergroup trial. Proceedings of the American Society for Clinical Oncology (ASCO), Denver, Co. J Clin Oncol 1997. Jacobs JR, Logemann J, Pajak TF, et al. Failure of cricopharyngeal myotomy to improve dysphagia following head and neck cancer surgery. Proceedings of the 101st meeting of the Annual Triological Society Meeting, San Franciaco, CA, 1997.

8610

GU

8610

GU

9406

GU

8610

GU

9805

GU

9210

GYN

8422

GYN

8005

GYN

9112

GYN

9210

GYN

8824

HN

8817

HN

8817

HN

8503

HN

8503, 9418

HN

8530

HN

(continued)

140

I. J. Radiation Oncology

● Biology ● Physics

Volume 51, Number 3, Supplement 2, 2001

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Lee WR, Berkey B, Marcial V, et al. Anemia: Friend or foe? Low hemoglobin is associated with decreased survival, loco-regional control and late complications: A secondary analysis or RTOG 85-27. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997 ;39:308. Al-Sarraf M, LeBlanc M, Giri P, et al. Chemo-Radiotherapy (CT-RT) vs. radiotherapy (RT) in patients (Pts.) with advanced nasopharyngeal cancer (NPC)—Intergroup (0099) SWOG 8892, RTOG 8817, ECOG 2388 phase III study: Progress report. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:385a. Lee D, Pajak T, Marcial V, et al. Long term results of a phase III etanidazole trial for locally advanced head & neck carcinomas. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:384a. Aref A, Berkey B, Schwade J, et al. The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: Secondary analysis of RTOG 8503. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, TX. Int J Radiat Oncol Biol Phys 1999; 45:274. Fu K, Pajak T, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: Preliminary results of RTOG 9003. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, TX. Int J Radiat Oncol Biol Phys 1999; 15:115. Khuri F, Lee J, Winn R, et al. The rate of SPT development in a randomized chemoprevention trial of HNSCC. Ninth International Congress on Anticancer Treatment, Paris, France, 1999. Bourhis J, Lapeyre M, Rives M, et al. Very accelerated radiotherapy in HNSCC: Results of the GORTEC 94-02 randomized trial. Proceedings of the American Society for Clinical Oncology (ASCO), New Orleans, LA. J Clin Oncol 2000; 19:412a. Cooper J, Berkey B, Marcial V, et al. Validation of the RTOG recursive partitioning analysis for head and neck cancers. Final program and abstract book: 5th International Conference on Head and Neck Cancer, San Francisco, 2000. p. 108. Fisher J, Scott C, Fu K, et al. Randomized study comparing quality of life (QOL) between standard fractionation radiotherapy (RT) and altered fractionation schemas in patients with locally advanced squamous cell cancer of the head and neck: A companion study for Radiation Therapy Oncology Group (RTOG) 90-03. Final program and abstract book: 5th International Conference on Head and Neck Cancer, San Francisco, 2000. p. 117. Hammond E, Berkey B, Fu K, et al. Is p53 a marker of radioresistence in head and neck cancer? A laboratory correlative study from RTOG 90-03. San Francisco; American Association for Cancer Research (AACR); 2000. Hammond E, Pajak T, Fu K, et al. p105 as a prognostic indicator in patients irradiated for locally advanced head and neck cancer: A clinical laboratory correlative analysis of RTOG 9003. Final Program and Abstract Book: 5th International Conference on Head and Neck Cancer, San Francisco, 2000. p. 145. Kim E, Khuri F, Lee J, et al. Second primary tumor incidence by primary index tumor and smoking status on a randomized chemoprevention study in head and neck squamous cell cancer. Proceedings of the American Society for Clinical Oncology (ASCO), New Orleans, LA. J Clin Oncol [19]. pg. 416a, Abs. #1642, 2000. Kumar P, Harris J, Robbins KT, et al. The feasibility of using intra-arterial cisplatin & radiation therapy for stage IV-T4 head/neck squamous cell carcinoma in a multi-institutional setting: Preliminary results of Radiation Therapy Oncology Group (RTOG) trial 96-15. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:152. Robbins KT, Harris J, Kumar P, et al. Targeted chemoradiation (RTOG 96-15) (RADPLAT) for T4 carcinoma of the upper aerodigestive tract: Interim analysis of a multi-institutional trial. Final Program and Abstract Book: 5th International Conference on Head and Neck Cancer, San Francisco, 2000. p. 78. Spencer S, Harris J, Wheeler R, et al. RTOG 96-10: Phase 1 study of reirradiation (RRT) with concurrent hydroxyurea (HU) and 5-Fluorouracil (FU) in Patients Pts with squamous cell cancer of the head and neck (SCH&N). Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:177–178. Al-Sarraf M, LeBlanc M, Giri PS, et al. Superiority of five year survival with chemoradiotherapy (CT-RT) vs radiotherapy in patients (Pts) with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III Study: Final Report. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:227a.

8527

HN

8817

HN

8527

HN

8503

HN

9003

HN

HN 9003

HN

8527

HN

9003

HN

9003

HN

9003

HN

9115

HN

9615

HN

9615

HN

9610

HN

8817

HN

(continued)

RTOG publications since 1996

141

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Garden AS, Pajak T, Vokes E, et al. Preliminary results of RTOG 9703—A phase II randomized trial of concurrent radiation (RT) and chemotherapy for advanced squamous cell carcinomas (SCC) of the head and neck. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:223a. Konski A, Scott C, Ang K, et al. Does dose escalation of radiotherapy (RT) improve qualityadjusted survival (QAS) in unresectable head and neck cancer (HNC) patients (Pts)? Radiation Therapy Oncology Group (RTOG) Study 90-03. Proceeding of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:227a. Kumar P, Robbins KT, Harris J, et al. Intra-arterial (IA) cisplatin (P) and radiation therapy (RT) is feasible in a multi-institutional setting for the treatment of stage IV-T4 head/neck (H/N) squamous cell carcinoma (SCCa): Initial results of radiation Therapy Oncology Group (RTOG) trial 9615. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:230a. Scarantino C, Leveque FG, Scott C, et al. A phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&N) cancer patients: RTOG 9709. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:225a. Forastiere A, Berkey B, Maor M, et al. Phase III trial to preserve the larynx: Induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, intergroup Trial R91-11. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:2a. Wheeler R, Harris J, Spencer S, et al. RTOG 9610—Phase II study of reirradiation (RRT) with concurrent hydroxyurea (HU) and 5-fluorouracil (FU) in patients (Pts) with recurrent squamous cell cancer of the head and neck: Survival results. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20:222a. Hammond E, Pajak T, Fu K, p105 as a prognostic indicator in patients irradiated for locally advanced head and neck cancer: A clinical laboratory correlative analysis of RTOG 9003. National Cancer Institute–European Organization for the Research and Treatment of Cancer Meeting. In press. Emami B, Scott C, Byhardt R, et al. The value of regional nodal radiotherapy (dose/volume) in the treatment of unresectable non-small cell lung cancer: An RTOG analysis. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO). Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:209. Komaki R, Scott C, Ettinger D, et al. Randomized phase II study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small cell cancer: RTOG 9204. Proceedings of the American Society for Clinical Oncology (ASCO), Philadelphia, PA. J Clin Oncol 1996; 15:514. Johnson D, Kim K, Sause W, et al. Cisplatin (P) & etoposide (E) ⫹ thoracic radiotherapy (TRT) administered once or twice daily (BID) in limited stage (LS) small cell lung cancer (SCLC): Final report of intergroup trial 0096. Proceedings of the American Society for Clinical Oncology (ASCO), Philadelphia, PA. Proc Am Soc Clin Oncol 1996; 15:374. Komaki R, Scott CB, Sause WT, et al. Induction cisplatin/vinblastine decreased distant metastasis in unresectable squamous cell lung cancer (SCC): Failure patterns in RTOG 88-08/ECOG 4588. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, CA. Int J Radiat Oncol Biol Phys 1996; 36:206. Herskovic A, Scott C, Demas W, et al. Accelerated Hyperfractionation for bronchogenic cancer—RTOG T.I.D. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:314. Roach M, Pajak T, Byhardt R, et al. The impact of radiation dose and fractionation on the risk factor of radiation pneumonitis on four Radiation Therapy Oncology Group (RTOG) lung cancer trials. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:321. Byhardt R, Scott C, Sause W, et al. Toxicity in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) radiation therapy (RT) for locally advanced non-small cell carcinoma of the lung (NSCLC). Eighth World Conference on Lung Cancer, Dublin, Ireland. J Int Assoc Lung Cancer 1997; 18:64. Byhardt R, Kolesar P, Sause W, et al. Response failure patterns and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) radiation therapy (RT) for locally advanced non-small cell carcinoma. Eighth World Conference on Lung Cancer, Dublin, Ireland. J Int Assoc Lung Cancer 1997; 18:62.

9703

HN

9003

HN

9615

HN

9709

HN

9111

HN

9610

HN

9003

HN

7811, 7917, 8311, 8407

Lung

9204

Lung

Lung

8808

Lung

9205

Lung

8311, 8321, 8403, 8407

Lung

8804, 8808, 9015, 9106

Lung

8804, 8808, 9015, 9106

Lung

(continued)

142

I. J. Radiation Oncology

● Biology ● Physics

Volume 51, Number 3, Supplement 2, 2001

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Byhardt R, Scott C, Sause W, et al. Response, toxicity, failure patterns and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) and radiation therapy (RT) for locally advanced non-small cell carcinoma of the lung (NSCLC). Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:195. Cox J, Scott C, Emami B, et al. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): Analysis of Radiation Therapy Oncology Group (RTOG) trials. Eighth World Conference on Lung Cancer, Dublin, Ireland. J Int Assoc Lung Cancer 1997; 18:126. Inculet R, Scott C, Dar R, et al. Phase III study comparing chemotherapy and radiation therapy with preoperative chemotherapy and surgical resection in patients with non-small cell lung cancer (NSCLC) with spread to mediastinal lymph nodes (N2): A Radiation Therapy Oncology Group study (RTOG 89-01). Proceedings of the Eighth World Conference on Lung Cancer, Dublin, Ireland. J Int Assoc Lung Cancer 1997. Komaki R, Scott C, Byhardt R, et al. Failure patterns by prognostic group as determined by recursive partitioning analysis (RPA) of 1,547 on four Radiation Therapy Oncology Group studies in operable non-small cell lung cancer (NSCLC). Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:196. Scott C, Sause W, Johnson D, et al. Factors which influence quality of life in patients with nonsmall cell lung cancer (NSCLC): A Radiation Therapy Oncology Group (RTOG 89-01). Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:198. Scott C, Movsas B, Sause W, et al. Intensified treatment increases survival in patients with nonsmall cell lung cancer (NSCLC) at what price? A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemo-radiation studies. Proceedings of the International Society for Quality of life Research, Vienna, Austria, Qual Life Res 1997; 6:718. Werner-Wasik M, Scott C, Graham M, et al. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with hyperfractionated radiotherapy with/without chemotherapy: A multivariate analysis of 682 RT patients. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL. Int J Radiat Oncol Biol Phys 1997; 39:314. Glisson B, Scott C, Komaki R, et al. Cisplatin (P), ifosfamide (I), prolonged oral etoposide (E), and concurrent accelerated hyperfractionated thoracic radiotherapy (TRT) for patients with limited small cell lung cancer (LSCLC): Preliminary results of a phase II trial. Eighth World Conference on Lung Cancer, Dublin, Ireland. J Int Assoc Lung Cancer 1997; 18:89. Hartsell W, Scott C, Dundas G, et al. Correlation of pulmonary function tests (PFTs), respiratory symptoms and baseline dyspnea index in patients with lung cancer: Analysis of RTOG 91-03. Proceedings of the International Society for Quality of Life Research (ISOQOL), Baltimore, MD. Qual Life Res 1998; 7:664. Lippman S, Lee J, Karp D, et al. Phase III intergroup trial of 13-cis-retinoic acid to prevent second primary tumors in stage 1 non-small cell lung cancer (NSCLC): Interim report of NCI #191-0001. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:456a. Machtay M, Seiferheld W, Cox J, et al. Are patients with supraclavicular node metastases in nonsmall cell lung cancer (NSCLC) curable with chemoradiotherapy? An analysis of the RTOG experience. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:168. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histologydependent in patients with locally advanced non-small cell lung cancer (NSCLC): A qualityadjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemo-radiation studies. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:203. Sause W, Kolesar P, Taylor S, et al. Five-year results: Phase III trial of regionally advanced unresctable non-small cell lung cancer, RTOG 8808, ECOG 4588, SWOG 8992. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:453a. Werner-Wasik M, Scott C, Cox J, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally advanced non-small cell lung cancer (LA-NSCLC): Identification of five groups with different survival. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17:460a.

8804, 8808, 9015, 9106

Lung

Miscellaneous

Lung

8901

Lung

8311, 8321, 8403, 8407

Lung

8901

Lung

Miscellaneous

Lung

8311, 8808, 9015, 9106

Lung

9312

Lung

9103

Lung

9101

Lung

Miscellaneous

Lung

Miscellaneous

Lung

8808

Lung

Miscellaneous

Lung

(continued)

RTOG publications since 1996

143

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Glisson B, Scott C, Komaki R, et al. Cisplatin (P), ifosfamide (I), prolonged oral etoposide (E) (PIE), and concurrent accelerated hyperfractionated thoracic radiotherapy (TRT) for patients with limited small cell lung cancer (LSCLC): Results of RTOG 93-12. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17: 450a. Albain K, Rusch V, Turrisi A, et al. Interim update of the National Cancer Institute high priority North American intergroup trial 0139 (RTOG 9309) for stage IIIa (N2) non-small cell lung cancer: A phase III comparison of concurrent chemotherapy plus standard radiotherapy versus concurrent chemotherapy plus radiotherapy followed by surgical resection. Perugia International Conference IV, 1999. Keller S, Adak S, Wagner H, et al. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: An intergroup trial (E3590). Proceedings of the American Society for Clinical Oncology (ASCO), Atlanta, GA. J Clin Oncol 1999 ;18:465a. Keller S, Adak S, Wagner H, et al. Randomized prospective comparison of adjuvant mediastinal radiation (RT) with or without concurrent chemotherapy with cisplatin and etoposide (PE) for patients with completely resected 51-3N1-2M0 non-small cell lung cancer (NSCLC): US lung intergroup trial 0115. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, TX. Int J Radiat Oncol Biol Phys 1999; 45: 145–146. Lee J, Scott C, Komaki R, et al. Effects of the number of patients treated per institution on the outcome of therapy in patients with locally-advanced inoperable non-small cell lung cancer: RTOG 91-06 and RTOG 92-04. Proceedings of the American Society for Clinical Oncology (ASCO), Atlanta, GA. J Clin Oncol 1999; 18:459a. McDonald S, Scott C, Rubin P, et al. A phase III study evaluating the efficacy of conventional radiation therapy with or without recombinant-interferon for patients with locally advanced non-small cell lung cancer and poor prognostic characteristics (RTOG 93-04). Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, TX. Int J Radiat Oncol Biol Phys 1999; 45:379–380. Schiller J, Adak S, Foins B, et al. Prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer: Preliminary results from a prospective randomized trial of postoperative adjuvant therapy (intergroup trial 0115). Proceedings of the American Society for Clinical Oncology (ASCO), Atlanta, GA. J Clin Oncol 1999; 18:464a. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemo radiation for Pts. with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 94-10. Proceedings of the American Society for Clinical Oncology (ASCO), New Orleans, LA. J Clin Oncol 2000; 19:484a. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemoradiation for Pts. with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiaton Therapy Oncology Group (RTOG) 9410. Ninth World Conference on Lung Cancer (IASLC), Toyko, Japan, 2000. Graham M, Paulus R, Wasserman T, et al. Preliminary results of a Radiation Therapy Oncology Group (RTOG) trial 97-05, a phase II study of postoperative adjuvant therapy in patients with completely resected stage II and stage IIIa non-small cell lung cancer. Ninth World Conference on Lung Cancer (IASLC), Tokyo, Japan, 2000. Komaki R, Seiferheld W, Ettinger D, et al. Randomized chemoradiation for patients with locally advanced inoperable non-small cell lung cancer (NSCLC): Long-term follow-up of RTOG 92-04. Ninth World Conference on Lung Cancer (IASLC), Tokyo, Japan, 2000. Komaki R, Seiferheld W, Curran W, et al. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410). Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:113. Konski A, Scott C, Movsas B, et al. Cost-utility analysis of various treatments for non-small cell carcinoma of the lung. Proceedings from the European Organization for Research and Treatment of Cancer Conference, Brussels, Belgium. Eur J Cancer 2000. Langer C, Scott C, Byhardt R, et al. Effect of advanced age on Outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC. Ninth World Conference on Lung Cancer (IASLC), Tokyo, Japan, 2000. Movsas B, Scott C, Sause W, et al. A quality-adjusted time without symptoms or toxicity (QTWIST) analysis of the Radiation Therapy Oncology Group (RTOG) chemoradiation studies for locally advanced non-small cell lung Cancer (LA-NSCLC). Proceedings of the American Radium Society, London, England, April 1–5, 2000, 2000. p. 31–32.

9312

Lung

9309

Lung

9105

Lung

9105

Lung

9106, 9204

Lung

9304

Lung

9409

Lung

9410

Lung

9410

Lung

9705

Lung

9204

Lung

9410

Lung

Miscellaneous

Lung Lung

8311, 8804, 8808, 9015

Lung

(continued)

144

I. J. Radiation Oncology

● Biology ● Physics

Volume 51, Number 3, Supplement 2, 2001

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Movsas B, Scott C, Sause W, et al. Age dramatically impacts on the quality-adjusted time without symptoms of toxicity (Q-Twist) in locally advanced non-small cell lung cancer—A RTOG analysis. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA. Int J Radiat Oncol Biol Phys 2000; 48:157–158. Sause W, Scott C, Byhardt R, et al. Combined chemotherapy radiation therapy treatment in unresectable non-small cell lung cancer Radiation Therapy Oncology Group (RTOG) experience. Ninth World Conference on Lung Cancer (IASLC), Toyko, Japan, 2000. Ettinger D, Seiferheld W, Abrams R, et al. Cisplatin (P), etoposide (E), pacitaxel (T) and concurrent hyperfractionated thoracic radiotherapy (TRT) for patients (Pts) with limited disease (LD) small cell lung cancer (SCLC): Preliminary results of RTOG 96-09. Proceedings of the American Society for Clinical Oncology (ASCO), New Orleans, LA. J Clin Oncol 2000; 19: 490a. Movsas B, Scott C, Curran W Jr, et al. A quality-adjusted time without symptoms or toxicity (QTWiST) analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proceedings of the American Society for Clinical Oncology (ASCO), San Francisco, CA. J Clin Oncol 2001; 20: 313a. Scott C, Scarantino C, Watkins Bruner D, et al. Late effects of normal tissue in head and neck and prostate cancer patients treated with radiation therapy. Research Issues in Cancer Survivorship (NCI Workshop), Bethesda, MD, 1998. Owen J, Grigsby P, Caldwell T, et al. Can costs be measured and predicted by modelling within a cooperative clinical trials group? Economic methodological pilot studies of Radiation Therapy Oncology Group (RTOG) studies 90-03 and 91-04. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO). San Antonio, TX. Int J Radiat Oncol Biol Phys 1999; 45:225. Scott C, Stern J, Asbell S, et al. Quality of life of long-term survivors of head and neck or prostate cancer: Preliminary results from a survey of survivors from Radiation Therapy Oncology Group (RTOG) clinical trials. Proceedings of the Researchs of the International Society for Quality of Life Research (ISOQOL), Vancouver, Canada, Quality of Life Research, pg. Abs. 2000. Milanes-Yearsley M, Hammond E, Pajak T. Tissue micro arrays in immuno-histochemistry: A practical, cost-effective and time-effective research tool. Proceedings of the United States Canadian Academy of Pathology, Atlanta, GA. Mod Path 2001. p. 234A. Mittal BB, Scott CB, Myerson RJ, et al. A phase I/II study to evaluate radiation therapy and hyperthermia for deep-seated tumors: A report of RTOG 89-08. International Congress of Hyperthermia Oncology, Rome, 1996. Scott C, Choucair A, Urtasun R, et al. The influence of compliance on interpretation of results from Radiation Therapy Oncology Group study 91-14. Proceedings of the International Society for Quality of Life Research (ISOQOL), Manila, Philippines. Qual Life Res 1996; 6:425. Wasserman T, Scott C, Bruner D, et al. A successful group quality of life programme: Radiation Therapy Oncology Group (RTOG). Proceedings of the American Society for Quality of Life Research, Vienna, Austria. Qual Life Res 1997; 6:739–745. Pajak T, Welsh C, Caldwell T, et al. Radiation Therapy Oncology Group’s (RTOG) measured approach in implementing modern technologies for their clinical trials. Proceedings of the American Society for Clinical Oncology (ASCO), Los Angeles, CA. J Clin Oncol 1998; 17: 446a. Cleeland C, Janjan N, Curran W, et al. Results of a survey among RTOG physicians after the publication of the AHCPR guidelines for cancer pain management. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), Phoenix, AZ. Int J Radiat Oncol Biol Phys 1998; 42:161. Wasserman T, Scott C, Bruner D, et al. Quality of life research in the Radiation Therapy Oncology Group (RTOG). American Radium Society (ARS), Monte Carlo, Monaco, May 2–6 Am Rad Soc Proc 1998. Benedetti J, Bryant J, Gray R, et al. Data forms review and coordination: A joint project of the national cooperative adult cancer clinical trials groups. Proceedings of the Society for Clinical Trials, Anaheim, CA. J Soc Clin Trials 1999; 70:71s. Guo M, Elashoff R. A simulation study of the proposed random effectgs model for multioutcome repeated measurements. American Statistical Association; Baltimore: 1999 Joint Statistical Program. 1999. Martin E, Lustig R, Harris J, et al. Validation of the sampling technique used in the Radiation Therapy Oncology Group’s quality assurance program. Proceedings of the Society for Clinical Trials. Anaheim, CA. J Soc Clin Trials 1999; 20:68s.

8311, 8804, 8808, 9015

Lung

Miscellaneous

Lung

9609

Lung

9410

Lung

Miscellaneous

Multi

9003, 9104

Multi

Multi

Miscellaneous

Multi

8908

NSS

9114

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

9408

NSS

(continued)

RTOG publications since 1996

145

Table 2. Abstracts published (Cont’d) Abstract reference

Study

Site

Seiferheld W, Scott C, Byhardt R, et al. The triangular test reduces time to decision in phase II trials of survival: Results from the Radiation Therapy Oncology Group (RTOG). Proceedings of the Society for Clinical Trials, Anaheim, CA. J Soc Clin Trials 1999; 20;545. Seiferheld W, Scott C, Byhardt R, et al. Reduction in the time to analysis for phase II studies with survival endpoint: Examples using RTOG studies. Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, TX. Int J Radiat Oncol Biol Phys 1999; 45:318. Harris J, Green S, Motyka-Welsh E, et al. Radiation Therapy Oncology Group experience with the minimum eligibility checking developed by the Southwest Oncology Group. Society for Clinical Trials, Toronto, Canada. Control Clin Trials 2000; 21:1095. Ley J, Motyka-Welsh E, Kuhn K, et al. RTOG experience with implementing a paperless study chair review. Society for Clinical Trials, Toronto, Canada. Control Clin Trials 2000; 21:56s. Pajak T. Remote data entry in cancer cooperative group trials. Society for Clinical Trials, Toronto, Canada. Control Clin Trials 2000; 21:54s. Young B, Hoover D, Sabina S, et al. Determining the point at which Web-based clinical trials become cost effective. Society for Clinical Trials, Toronto, Canada. Control Clin Trials 2000; 21:435–445.

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Miscellaneous

NSS

Abbreviations as in Table 1.